MiRXES Lab Pte. Ltd. (Singapore)

MiRXES is a Singapore-headquartered RNA technology company that develops and commercializes non-invasive, blood-based microRNA (miRNA) test kits for the early detection of cancer and other diseases. The company spun off in 2014 from the A*STAR Bioprocessing Technology Institute with support from a TECS grant from Spring Singapore, and formed a strategic partnership with the Singapore Diagnostic Development Hub (DxD Hub) to translate miRNA cancer early-detection tests. Its mission is to make diagnostic solutions for the early detection of diseases accessible on a global scale. MiRXES is best known for GASTROClear, described by the company as the world's first molecular blood test for gastric cancer, which received regulatory approval in Singapore in 2019. The company also markets LUNGClear for lung cancer screening, APEX and COMPASS tissue tests for cancer treatment selection, and the ID3EAL suite of miRNA discovery tools and services. Beyond diagnostics, MiRXES Genomics provides spatial and single-cell multi-omics services, including next-generation sequencing and bioinformatics. The company has expanded internationally, establishing an R&D laboratory in Hangzhou and a clinical diagnostic laboratory in Tianjin in China, a US office, and a Japan office. It launched the M Diagnostics clinical laboratory in 2021 to serve Southeast Asia. During the COVID-19 pandemic, MiRXES mass-produced Singapore's first approved COVID-19 PCR test kit and deployed it to approximately 35 countries. It raised a USD$87M Series C in 2021, bringing total funding since inception to USD$130M. MiRXES has received numerous awards, including IVD Company of the Year at BioHK 2025 and Best Diagnostic Company of the Year at BioHK 2024. The company is listed on the Hong Kong Stock Exchange, and in January 2026 announced an HK$711 million placing agreement at HK$32.50 per share, 40% above its IPO price.

MiRXES was spun off in 2014 from the A*STAR Bioprocessing Technology Institute in Singapore, receiving a TECS grant from Spring Singapore. It formed a strategic partnership with the Singapore Diagnostic Development Hub (DxD Hub) to translate miRNA cancer early detection tests. In 2015, the company launched the ID3EAL suite of miRNA discovery tools and services for biopharma and life science research in the United States and Europe. In 2016, it established an ISO13485 compliant in vitro diagnostic (IVD) manufacturing site in Singapore, initiated large-scale prospective clinical validation of GASTROClear in a 5,000-patient high-risk cohort, and entered the Chinese market with an R&D laboratory in Hangzhou. In 2017, GASTROClear obtained CE registration, and the company initiated global collaborations in oncology, cardiovascular, and metabolic diseases. In 2018, MiRXES established global partnerships with Johnson & Johnson and other multinational biopharma companies, set up joint R&D labs with Beth Israel Deaconess Medical Center in Boston and the National University of Singapore, and opened a US office. In 2019, GASTROClear received regulatory approval in Singapore for gastric cancer early detection. The company also established an ISO13485 compliant IVD manufacturing site in Hangzhou, China, and a clinical diagnostic laboratory in Tianjin, China. In 2020, MiRXES set up a Japan office, contributed to the world's first industry standard for miRNA-based diagnostics, and mass-produced Singapore's first approved COVID-19 PCR test kit, deploying it to approximately 35 countries during the pandemic. In 2021, it launched the M Diagnostics clinical laboratory to provide specialty clinical testing to Southeast Asia and raised USD$87M in Series C funding, bringing total funding since inception to USD$130M. The company has continued to expand its product portfolio and global presence, and is now listed on the Hong Kong Stock Exchange.

• 2026

  Announced HK$711 million placing agreement at HK$32.50 per share, 40% above IPO price.

• 2025

  Awarded IVD Company of the Year - Best Investment Value at BioHK 2025.

• 2024

  Awarded Best Diagnostic Company of The Year at BioHK 2024; recognized in China's 8th Healthcare Investment Excellent List and other awards.

• 2021

  Launched M Diagnostics clinical laboratory for Southeast Asia; raised USD$87M Series C, total USD$130M secured since inception.

• 2020

  Set up Japan office; contributed to world's first industry standard of miRNA-based diagnostics; mass produced Singapore's first approved COVID-19 PCR test kit and deployed to approximately 35 countries.

• 2019

  GASTROClear received regulatory approval in Singapore for gastric cancer early detection; established ISO13485 compliant IVD manufacturing site in Hangzhou, China; established clinical diagnostic laboratory in Tianjin, China.

• 2018

  Established global partnerships with Johnson & Johnson and other multinational biopharma companies; set up joint R&D labs with Beth Israel Deaconess Medical Center and the National University of Singapore; set up US office.

• 2017

  Obtained CE registration for GASTROClear; initiated global collaborations in oncology, cardiovascular, and metabolic diseases.

• 2016

  Established ISO13485 compliant IVD manufacturing site in Singapore; initiated large-scale prospective clinical validation of GASTROClear in a 5,000-patient high-risk cohort; entered Chinese market with R&D laboratory in Hangzhou.

• 2015

  Launched ID3EAL suite of miRNA discovery tools and services in the United States and Europe.

• 2014

  MiRXES Pte Ltd spun off from A*STAR Bioprocessing Technology Institute, received TECS grant from Spring Singapore; formed strategic partnership with DxD Hub.

Pioneer and leader in developing and commercializing accurate, non-invasive, and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases.

• GASTROClear

  World's first molecular blood test for gastric cancer early detection; received regulatory approval in Singapore in 2019 and CE registration in 2017.

• LUNGClear

  Blood test for lung cancer screening.

• APEX Tissue

  Targeted Next Generation Sequencing (NGS) test for cancer treatment selection.

• COMPASS Tissue

  Comprehensive Next Generation Sequencing (NGS) test for cancer treatment selection.

• ID3EAL Suite

  Class-leading, highly sensitive detection for miRNAs using proprietary ID3EAL RT-qPCR technology.

• Fortitude 2.1

  Product in the cancer care continuum portfolio.

• Fortitude Syndromic Panel

  Syndromic panel product.

• ID3EAL PanoramiR MiRNA Knowledge Panel

  miRNA knowledge panel for research.

1. 1Mirxes - Homemirxes.com
2. 2Mirxes - Our Storymirxes.com
3. 3Mirxes - Our Purposemirxes.com
4. 4Mirxes - Precision Multiomicsmirxes.com
5. 5MiRXES Lab Pte. Ltd. (Singapore) - Wikidatawikidata.org